CN101011377A - Application of compound s6 in the process for preparing anti-cancer medicament - Google Patents

Application of compound s6 in the process for preparing anti-cancer medicament Download PDF

Info

Publication number
CN101011377A
CN101011377A CNA2006100309186A CN200610030918A CN101011377A CN 101011377 A CN101011377 A CN 101011377A CN A2006100309186 A CNA2006100309186 A CN A2006100309186A CN 200610030918 A CN200610030918 A CN 200610030918A CN 101011377 A CN101011377 A CN 101011377A
Authority
CN
China
Prior art keywords
compound
present
application
cell
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006100309186A
Other languages
Chinese (zh)
Inventor
余龙
张昊星
郎庆宇
李佳
唐丽莎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fudan University
Original Assignee
Fudan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fudan University filed Critical Fudan University
Priority to CNA2006100309186A priority Critical patent/CN101011377A/en
Publication of CN101011377A publication Critical patent/CN101011377A/en
Priority to PCT/CN2007/070651 priority patent/WO2008040208A1/en
Priority to CN2007800330141A priority patent/CN101511355B/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Abstract

The invention relates to an application of compound S6 in the preparation of anti-tumor drug. The inventive S6 can restrain or kill kinds of tumor cells and cancer cells. And the compound S6 can restrain phosphokinase Aurora-B. The inventive compound S6 can be carried by medical carrier to prepare anti-tumor drug.

Description

The application of compound s 6 in the preparation cancer therapy drug
Technical field
The present invention relates to the cytobiology field, the application of compound s 6 in the preparation cancer therapy drug is provided.
Background technology
Tumor is the disease of serious harm human health.The sickness rate of tumor day by day increases in recent years, and the whole world has more than 600 ten thousand people to die from cancer every year at present, and new cases 8,000,000, this numeral are also increasing year by year.Have 1,000,000 New Development cancer patients every year in China's 1,300,000,000 populations, and patient to be treated about 2,000,000, dead about 1,300,000.Expect the end of the year in 2006, China will have 1,700,000 people to die from cancer, and cancer has become first cause of the death.
Malignant tumor is commonly called as cancer, is the lump unrestricted growth and diffusion that causes after the organ of human body and histiocyte morph.It can destroy the organ and the function of organization of human body, finite energy in the consumer, and people's vital movement is suffered damage, even cause death.
Mitosis is very important in a cell cycle process stage.Tumor and Normocellular difference are exactly unrestricted hypertrophy, and promptly mitosis loses normal regulation.Its occurrence cause of most tumor is the genomic unstability due to the mitosis, and genomic instability derives from chromosomal instability again, and chromosomal instability is the characteristic sign of cancer.Chromosomal separation, Centriolar duplicating with separating are taken place unusually, can cause the unusual of each cell chromosome number, both aneuploids, increase the chance of heterozygosity disappearance, the number increase of the disappearance of antioncogene or proto-oncogene all can make the conduction of metabolism of cell life and signal get muddled, and increases the chance of canceration.Kinases plays an important role in finishing mitosis and cell cycle regulating, thereby becomes present molecular biological research focus.
Summary of the invention
The purpose of this invention is to provide the application of compound s 6 in the preparation cancer therapy drug.
The invention provides structure as
Figure A20061003091800031
The application of shown chemical compound in the preparation cancer therapy drug.The name of above-claimed cpd be called (2Z)-2-(3,4-dihydroxybenzylidene)-1-benzofuran-3 (2H)-one, abbreviate S6 as, molecular weight is 254, can be by commercially available acquisition.The present invention comprises that also this chemical compound is carried out routine substitutes resulting chemical compound.
Among the present invention, compound s 6 can be used for preparing cancer therapy drug.
The present invention has detected the effect situation of compound s 6 for tumor cell and cancerous cell by standard MTS experiment, the result shows, S6 of the present invention is to kinds of tumor cells and cancerous cell, and for example hepatoma carcinoma cell, colon cancer cell, stomach cancer cell and lung carcinoma cell etc. all kill and wound or suppress effect.
Studies show that further compound s 6 of the present invention has inhibitory action to phosphokinase Aurora-B.This has confirmed that further compound s 6 of the present invention has the inhibition effect of malignant tumors.
Malignant tumor is commonly called as cancer, is the lump unrestricted growth and diffusion that causes after the organ of human body and histiocyte morph.Kinases plays an important role in finishing mitosis and cell cycle regulating, thereby becomes present molecular biological research focus.AIK (Aurora/Ipl1 Kinase) is present one of known five big modulability kinases families.Up to the present, human Aiks family finds three member: Aik1, Aik2 (Aurora-B) and Aik3 altogether.Wherein, Aik2 mainly works in the cell mitogen phase.It follows albumen to participate in regulating the interaction of centromere and spindle microtubule as chromosome, this is instantaneous in mid-term to the later stage, Aik2 migrates to cell mesozone band [Bischoff, J.R., Anderson by centromere, L., et al. (1998) EMBO J.17,3052-3065], be distributed in cell dish and back mitosis bridge latter stage, participate in back mitosis incident, thus with chromosomal separate with cytokinesis relevant.The sudden change of Aik2 is suppressed the formation of branch dehiscence furrow, and causes forming apocyte.Aik2 is positioned 17q13, and this zone occurs in the multiple cancerous cell of the mankind unusually, and in the colon cancer cell line of unusual ploidy the Aik2 high expressed.Therefore, the scientific research personnel seeks the molecule with the Aik2 effect one after another, and it is studied as antitumor drug.
The present invention has also set up the transplanted tumor mouse model, is used to detect the effect of S6 to in-vivo tumour and cancerous cell.The result shows that also S6 can suppress tumor growth in vivo.
Among the present invention, the pharmaceutical composition of forming by the compound s 6 that contains effective therapeutic dose and carrier pharmaceutically or excipient by the cancer therapy drug of compound s 6 preparation.
Among the present invention, described effective application quantity is mg/kg to 20 mg/kg body weight every day 0.1.
Among the present invention, prepared antitumor drug can be injection or tablet etc.
S6 of the present invention and analog thereof etc. when using (administration) in treatment, can provide different effects.Usually, can these materials are formulated in nontoxic, the inert and pharmaceutically acceptable aqueous carrier medium, wherein pH is about 5-8 usually, and preferably pH is about 6-8, although pH value can be with being changed to some extent by preparation Substance Properties and disease to be treated.The pharmaceutical composition for preparing can carry out administration by conventional route, comprising (but being not limited to): intramuscular, intraperitoneal, subcutaneous, Intradermal or topical.
With S6 of the present invention is example, can be with itself and suitable pharmaceutically acceptable carrier coupling.This class pharmaceutical composition contains protein and the pharmaceutically acceptable carrier or the excipient for the treatment of effective dose.This class carrier comprises (but being not limited to): saline, buffer, glucose, water, glycerol, ethanol and combination thereof.Pharmaceutical preparation should be complementary with administering mode.S6 of the present invention can be made into the injection form, for example is prepared by conventional method with normal saline or the aqueous solution that contains glucose and other adjuvant.Pharmaceutical composition such as tablet and capsule can be prepared by conventional method.Pharmaceutical composition such as injection, solution, tablet and capsule should be made under aseptic condition.The dosage of active component is the treatment effective dose, for example every day about 1 microgram/kg body weight-Yue 5 mg/kg body weight.In addition, S6 of the present invention also can use with the other treatment agent.
When S6 polypeptide of the present invention is used as medicine, this polypeptide of treatment effective dose can be applied to mammal, wherein should treat effective dose usually at least about 10 micrograms/kg body weight, and in most of the cases be no more than about 80 mg/kg body weight, preferably this dosage is about 500 micrograms/kg body weight-Yue 2 mg/kg body weight.Certainly, concrete dosage also should be considered factors such as route of administration, patient health situation, and these all are within the skilled practitioners skill.
Cancer has become first cause of the death, and the material of killing tumor cells and growth of cancer cells also becomes the research focus of present biological medicine circle thus.S6 of the present invention kills and wounds kinds of tumor cells and cancerous cell or suppresses effect; Simultaneously, compound s 6 of the present invention has inhibitory action to phosphokinase Aurora-B.This has proved that all compound s 6 of the present invention has the inhibition effect of malignant tumors.Compound s 6 of the present invention be can be used for preparing cancer therapy drug with suitable pharmaceutically acceptable carrier coupling, to suppress the tumor continued growth.
Description of drawings
Fig. 1 is that S6 suppresses figure as a result to the sw620 cell.As seen, S6 of the present invention is about 1 μ M to the IC50 (half causes death) of human colon's JEG-3 (sw620).
The specific embodiment
Embodiment 1 vitro enzyme is lived and is suppressed experiment
Use escherichia expression system, clone, expression and purification have obtained people source Aurora-B protein kinase (the NCBI number of landing is NP 004208), are used for the high flux screening screening experiment.Adopt radio isotope technique, AURORAB phosphorylated substrate MBP (UPSTATE company, CAT#13-110, lot#27845), with in the solution [γ- 33P]-γ on the ATP- 33P shifts and is covalently bound to substrate, makes its Ser phosphorylation, produces to have isotope-labeled substrate 33P-MBP.Add scintillation solution at last and count by liquid scintillation counter and detect this enzymatic activity, can observe different chemical compounds to its active inhibition situation, with the activity of preliminary assessment chemical compound.
The parallel laboratory test result shows that compound s 6 of the present invention is 15.59nM to the IC50 that the Aurora-B protein kinase activity suppresses.
Embodiment 2 cancerous cell suppress experiment
Carry out according to standard MTS experiment, wherein concrete parameter is as follows:
Plant plate: 1000 cells/well
Chemical compound: S6
Incubation time: 96h
Add medicine post processing time: 3h
Compound concentration gradient: unit: uM
Repeated experiments: 6 groups
Data provide form: mean+SD
Cell strain: human colon's JEG-3 (sw620)
The result shows that compound s 6 of the present invention is about 1 μ M to the IC50 that sw620 suppresses.Specifically see the following form:
Drug level (uM) 25 12.5 6.25 3.125 1.5625 0.78125 0.39062 5 0.19531 25 0
s6- sw620 0.00933 ± 0.00516 0.0138 ± 0.00248 0.0405 ± 0.00781 0.0482 ± 0.00752 0.0502 ± 0.00780 0.0527 ± 0.00463 0.0655 ± 0.0123 0.0783 ± 0.0111 0.102± 0.0129

Claims (5)

  1. Structure as
    The application of shown chemical compound in the preparation cancer therapy drug.
  2. 2. application as claimed in claim 1 is characterized in that, chemical compound shown in the claim 1 is used to prepare cancer therapy drug.
  3. 3. use according to claim 1, it is characterized in that, the pharmaceutical composition that this cancer therapy drug is made up of the chemical compound shown in claim 1 that contains the effect consumption and carrier pharmaceutically or excipient.
  4. 4. as application as described in the claim 3, it is characterized in that described effective application quantity is mg/kg to 20 mg/kg body weight every day 0.1.
  5. 5. use according to claim 1, it is characterized in that this cancer therapy drug is injection or tablet.
CNA2006100309186A 2006-09-07 2006-09-07 Application of compound s6 in the process for preparing anti-cancer medicament Pending CN101011377A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CNA2006100309186A CN101011377A (en) 2006-09-07 2006-09-07 Application of compound s6 in the process for preparing anti-cancer medicament
PCT/CN2007/070651 WO2008040208A1 (en) 2006-09-07 2007-09-07 (2z)-2-(3,4-dihydroxybenzylidene)-1-benzofuran-3(2h)-one in manufacture of medicaments for treating cancers
CN2007800330141A CN101511355B (en) 2006-09-07 2007-09-07 Application of (2Z)-2-(3, 4-dihydroxy bezilidene)-1-benzofuran-3(2H)-ketone for preparation of anti-cancer medicine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNA2006100309186A CN101011377A (en) 2006-09-07 2006-09-07 Application of compound s6 in the process for preparing anti-cancer medicament

Publications (1)

Publication Number Publication Date
CN101011377A true CN101011377A (en) 2007-08-08

Family

ID=38699213

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2006100309186A Pending CN101011377A (en) 2006-09-07 2006-09-07 Application of compound s6 in the process for preparing anti-cancer medicament
CN2007800330141A Expired - Fee Related CN101511355B (en) 2006-09-07 2007-09-07 Application of (2Z)-2-(3, 4-dihydroxy bezilidene)-1-benzofuran-3(2H)-ketone for preparation of anti-cancer medicine

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2007800330141A Expired - Fee Related CN101511355B (en) 2006-09-07 2007-09-07 Application of (2Z)-2-(3, 4-dihydroxy bezilidene)-1-benzofuran-3(2H)-ketone for preparation of anti-cancer medicine

Country Status (2)

Country Link
CN (2) CN101011377A (en)
WO (1) WO2008040208A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101511355B (en) * 2006-09-07 2012-11-21 复旦大学 Application of (2Z)-2-(3, 4-dihydroxy bezilidene)-1-benzofuran-3(2H)-ketone for preparation of anti-cancer medicine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2084208A1 (en) * 1990-05-17 1991-11-18 Barry Markaverich Growth inhibitors and methods of treating cancer and cell proliferative diseases
WO2002083123A1 (en) * 2001-04-18 2002-10-24 Pharmacia Italia Spa Aurones as telomerase inhibitors
US7220764B2 (en) * 2002-06-17 2007-05-22 The Pennsylvania State University Research Foundation Sphingosine kinase inhibitors
CN101011377A (en) * 2006-09-07 2007-08-08 复旦大学 Application of compound s6 in the process for preparing anti-cancer medicament

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101511355B (en) * 2006-09-07 2012-11-21 复旦大学 Application of (2Z)-2-(3, 4-dihydroxy bezilidene)-1-benzofuran-3(2H)-ketone for preparation of anti-cancer medicine

Also Published As

Publication number Publication date
CN101511355B (en) 2012-11-21
WO2008040208A1 (en) 2008-04-10
CN101511355A (en) 2009-08-19

Similar Documents

Publication Publication Date Title
CN101612400A (en) 1 application of receptor antagonist in antitumor of angiotensin
CN107260734B (en) Compound pharmaceutical composition with anti-lung cancer effect and application thereof
US20190183893A1 (en) Low dose of sildenafil as an antitumor drug
CN105380956B (en) A kind of pharmaceutical composition of Dana Delany containing Chinese mugwort for treating leukaemia and application
CN106974908A (en) Pharmaceutical composition and purposes containing hdac inhibitor and IRE1 inhibitor
CN109793727A (en) A kind of pharmaceutical composition and its application of effective anti-malignant tumor
CN101167741B (en) Sulforaphane and platinum medicine anti-cancer combination preparation
CN101011377A (en) Application of compound s6 in the process for preparing anti-cancer medicament
CN101112371B (en) Application of compound s2 in the preparation of anti-cancer medicine
CN101112368A (en) Application of compound s4 in the preparation of anti-cancer medicine
CN115300624A (en) Application of ginsenoside and PD-1 blocker in preparation of head and neck squamous cell carcinoma resisting medicine
US20230172957A1 (en) Use of astragalus medicinal composition for preparing drug for enhancing cancer therapy
CN111494385B (en) Medicine for treating ovarian cancer and preparation method and application thereof
CN101112372A (en) Application of compound s1 in the preparation of anti-cancer medicine
JPH10511677A (en) Use of inositol triphosphate for drug preparation.
CN113440534A (en) Application of verbascoside in preparation of medicines
CN102526046A (en) Antitumor medicinal composition containing epigallocatechin gallate (EGCG) and sorafenib and application thereof
CN105147695A (en) Anti-breast cancer powder containing metformin hydrochloride and gdc 0941
CN112076216A (en) Application of arsenic trioxide in treating gastrointestinal stromal tumor
CN102440994A (en) Application of ganoderic acid G as immune synergist and super-antigen dependent therapeutic medicine in tumour treatments
CN111407748B (en) Application of tyrosol in preparation of medicine for treating brain glioma
CN102526033B (en) Composition prepared from epigallocatechin gallate and mitomycin C and used for suppressing tumor cell proliferation
US20060039999A1 (en) Pharmaceutical composition for inhibition of tumor growth or metastasis
CN102526081A (en) Medicinal composition capable of inhibiting proliferation of tumor cells
CN106668061B (en) A kind of anticancer pharmaceutical composition containing cis-platinum

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication